An overview of the Canadian landscape on the use of restorative therapies for erectile dysfunction and Peyronie’s disease

Q3 Medicine

Canadian Urological Association Journal Pub Date : 2024-07-15 DOI:10.5489/cuaj.8804

Jainik Shah, M. Fidel, Dhiraj S. Bal, A. Kharazi, Connor Roque, Yool Ko, K. Sidhom, David Bouhadana, Francis Petrella, Premal Patel

{"title":"An overview of the Canadian landscape on the use of restorative therapies for erectile dysfunction and Peyronie’s disease","authors":"Jainik Shah, M. Fidel, Dhiraj S. Bal, A. Kharazi, Connor Roque, Yool Ko, K. Sidhom, David Bouhadana, Francis Petrella, Premal Patel","doi":"10.5489/cuaj.8804","DOIUrl":null,"url":null,"abstract":"Introduction: Restorative therapies (RT(s)), including low-intensity shockwave therapy (Li-SWT) and platelet-rich plasma (PRP), aim to restore natural erectile function. Many clinics offer these therapies for erectile dysfunction (ED) and Peyronie’s disease (PD) with direct-to-consumer (DTC) marketing. This study sought to investigate the landscape of RTs within Canadian clinics.\nMethods: Online searches were made to identify clinics offering Li-SWT and/or PRP as an RT for treating ED and PD in Canada. Public websites were analyzed, followed by calling clinics for data on cost, treatment protocols, clinic ownership, success rates, and adjunctive therapies.\nResults: A total of 107 clinics were identified online, with a 68.2% call response rate (n=73). Of the respondents, 56 and 40 clinics provided Li-SWT and PRP therapies, respectively, with 23 clinics offering both. All clinics reported using RTs for ED, with 21 clinics offering Li-SWT and 22 clinics providing PRP for PD. Forty-three clinics provided costs and protocols for Li-SWT, while 33 clinics did so for PRP. The average cost + standard deviation (CAD) of six sessions of Li-SWT was $2167.24+936.11 and one shot of PRP was $1478.68+591.98. Most (60.3%, n=44) clinics reported physician ownership, with a majority (n=28) being family medicine trained. Seven clinics did not provide data and 22 were non-MD-owned. Ten clinics provided success rates, with an average of 87.3%.\nConclusions: Despite limited data supporting their routine clinical use, many clinics across Canada offer RTs for ED and PD with varying treatment protocols and increased costs. Further research is required to evaluate the efficacy of RT for ED and PD.","PeriodicalId":38001,"journal":{"name":"Canadian Urological Association Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Urological Association Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5489/cuaj.8804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Restorative therapies (RT(s)), including low-intensity shockwave therapy (Li-SWT) and platelet-rich plasma (PRP), aim to restore natural erectile function. Many clinics offer these therapies for erectile dysfunction (ED) and Peyronie’s disease (PD) with direct-to-consumer (DTC) marketing. This study sought to investigate the landscape of RTs within Canadian clinics. Methods: Online searches were made to identify clinics offering Li-SWT and/or PRP as an RT for treating ED and PD in Canada. Public websites were analyzed, followed by calling clinics for data on cost, treatment protocols, clinic ownership, success rates, and adjunctive therapies. Results: A total of 107 clinics were identified online, with a 68.2% call response rate (n=73). Of the respondents, 56 and 40 clinics provided Li-SWT and PRP therapies, respectively, with 23 clinics offering both. All clinics reported using RTs for ED, with 21 clinics offering Li-SWT and 22 clinics providing PRP for PD. Forty-three clinics provided costs and protocols for Li-SWT, while 33 clinics did so for PRP. The average cost + standard deviation (CAD) of six sessions of Li-SWT was $2167.24+936.11 and one shot of PRP was $1478.68+591.98. Most (60.3%, n=44) clinics reported physician ownership, with a majority (n=28) being family medicine trained. Seven clinics did not provide data and 22 were non-MD-owned. Ten clinics provided success rates, with an average of 87.3%. Conclusions: Despite limited data supporting their routine clinical use, many clinics across Canada offer RTs for ED and PD with varying treatment protocols and increased costs. Further research is required to evaluate the efficacy of RT for ED and PD.

查看原文本刊更多论文

加拿大使用恢复性疗法治疗勃起功能障碍和佩罗尼氏病的概况

导言：修复疗法（RT），包括低强度冲击波疗法（Li-SWT）和富血小板血浆疗法（PRP），旨在恢复自然勃起功能。许多诊所通过直接面向消费者（DTC）的营销方式提供这些治疗勃起功能障碍（ED）和佩罗尼氏病（PD）的疗法。本研究旨在调查加拿大诊所内的 RTs 情况：方法：进行在线搜索，以确定加拿大提供Li-SWT和/或PRP作为治疗ED和PD的RT的诊所。对公共网站进行了分析，然后致电诊所了解有关费用、治疗方案、诊所所有权、成功率和辅助疗法的数据：结果：共在网上找到 107 家诊所，电话回复率为 68.2%（n=73）。在受访者中，分别有 56 家和 40 家诊所提供 Li-SWT 和 PRP 疗法，其中 23 家诊所同时提供这两种疗法。所有诊所均报告使用 RT 治疗 ED，其中 21 家诊所提供 Li-SWT 治疗，22 家诊所提供 PRP 治疗 PD。43 家诊所提供了 Li-SWT 的成本和方案，33 家诊所提供了 PRP 的成本和方案。6次Li-SWT治疗的平均费用+标准差（CAD）为2167.24+936.11美元，1次PRP治疗的平均费用为1478.68+591.98美元。大多数（60.3%，n=44）诊所报告了医生所有权，其中大多数（n=28）接受过家庭医学培训。7家诊所未提供数据，22家为非医生所有。10家诊所提供了成功率，平均成功率为87.3%：尽管支持其常规临床应用的数据有限，但加拿大各地的许多诊所都提供治疗 ED 和 PD 的 RT，但治疗方案各不相同，费用也有所增加。需要进一步开展研究，评估 RT 治疗 ED 和 PD 的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Canadian Urological Association Journal Medicine-Urology

CiteScore

2.10

自引率

0.00%

发文量

167

期刊介绍： Published by the Canadian Urological Association, the Canadian Urological Association Journal (CUAJ) released its first issue in March 2007, and was published four times that year under the guidance of founding editor (Editor Emeritus as of 2012), Dr. Laurence H. Klotz. In 2008, CUAJ became a bimonthly publication. As of 2013, articles have been published monthly, alternating between print and online-only versions (print issues are available in February, April, June, August, October, and December; online-only issues are produced in January, March, May, July, September, and November). In 2017, the journal launched an ahead-of-print publishing strategy, in which accepted manuscripts are published electronically on our website and cited on PubMed ahead of their official issue-based publication date. By significantly shortening the time to article availability, we offer our readers more flexibility in the way they engage with our content: as a continuous stream, or in a monthly “package,” or both. CUAJ covers a broad range of urological topics — oncology, pediatrics, transplantation, endourology, female urology, infertility, and more. We take pride in showcasing the work of some of Canada’s top investigators and providing our readers with the latest relevant evidence-based research, and on being the primary repository for major guidelines and other important practice recommendations. Our long-term vision is to become an essential destination for urology-based research, education, and advocacy for both physicians and patients, and to act as a springboard for discussions within the urologic community.